Potential Cialis switch and the pending addition of Boehringer Ingelheim's consumer business are the revenue drivers highlighted by company execs on earnings call; second-quarter consumer health product revenues slipped 4.3% to $886.4m as a mild allergy season in the US and economic chaos in Venezuela drag down sales.
Sanofi is working to "fine-tune" an application to make erectile dysfunction drug Cialis available OTC in the US, marking another potential boost for its consumer health care segment on top of adding Boehringer Ingelheim GMBH's consumer business.
After Sanofi's second-quarter consumer health product revenues slipped 4.3% to €800m ($886.4m) as a mild allergy season in the US...
Germany’s Expert Committee for Prescription supports the Rx-to-OTC switches of melatonin and buccal acyclovir but rejects rupatadine.
Navamedic adds Ventizolve to its portfolio shortly after Norway switched the opioid overdose reversal drug from Rx to OTC.
Now available without a prescription, Dymista Control is the first OTC combination treatment for consumers who are struggling to control their seasonal allergic rhinitis with a corticosteroid or antihistamine nasal spray, according to the firm.
Creating a working group to drive Rx-to-OTC switch is one of the ways in which Finland could expand self-care and save €60m per year for the country's health system, suggests a recently published report commissioned by Haleon.
Germany’s Expert Committee for Prescription supports the Rx-to-OTC switches of melatonin and buccal acyclovir but rejects rupatadine.
A round-up of the latest European people moves: BioGaia hires new subsidiary head from L'Oréal; Assosalute gets new director; Bayer renews contract of CEO.
Senate appropriators also put FDA on notice regarding recent meetings and compliance with the Federal Advisory Committees Act, signal positive news on rare pediatric diseases, and offer hints of other agency areas they have close eyes on.
